^
Association details:
| Biomarker: | EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
Published date:
06/19/2020
Excerpt:
Off-label oral cabozantinib 60 mg daily was added to oral osimertinib 80 mg daily in an effort to target these MET mutations (Table 1). Although he achieved stable disease (Fig. 1), he developed considerable fatigue, gastrointestinal toxicity, and cytopenias on dual-inhibitor therapy, thus requiring cessation of cabozantinib. A repeat liquid biopsy revealed the original truncal EGFR mutation, MET amplification, and the known MET-D1228X mutations (Fig. 1). He was continued on osimertinib but died after 3 months.
DOI:
10.1016/j.jtocrr.2020.100071
